Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Beyond Air Inc XAIR

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire October 20, 2022

Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022

GlobeNewswire October 17, 2022

Beyond Cancer(TM) to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting

GlobeNewswire October 5, 2022

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

GlobeNewswire October 3, 2022

Beyond Air® To Participate in Three Upcoming Investor Conferences

GlobeNewswire September 16, 2022

Beyond Air® Affiliate Beyond Cancer(TM) Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)

GlobeNewswire August 23, 2022

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023

GlobeNewswire August 11, 2022

Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire July 27, 2022

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

GlobeNewswire June 28, 2022

Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

GlobeNewswire June 28, 2022

Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

GlobeNewswire June 14, 2022

Beyond Cancer(TM) Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

GlobeNewswire June 1, 2022

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

GlobeNewswire May 17, 2022

Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

GlobeNewswire May 17, 2022

Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

GlobeNewswire May 16, 2022

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

GlobeNewswire April 25, 2022

Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022

GlobeNewswire April 25, 2022

Beyond Air® to Participate in Three Upcoming Medical Conferences

GlobeNewswire April 18, 2022

Beyond Cancer(TM) Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

GlobeNewswire April 11, 2022

Beyond Cancer(TM) to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

GlobeNewswire March 8, 2022